These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36387285)

  • 1. Reduction of kinesin I heavy chain decreases tau hyperphosphorylation, aggregation, and memory impairment in Alzheimer's disease and tauopathy models.
    Selvarasu K; Singh AK; Iyaswamy A; Gopalkrishnashetty Sreenivasmurthy S; Krishnamoorthi S; Bera AK; Huang JD; Durairajan SSK
    Front Mol Biosci; 2022; 9():1050768. PubMed ID: 36387285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of Tau with Kinesin-1: Effect of Kinesin-1 Heavy Chain Elimination on Autophagy-Mediated Mutant Tau Degradation.
    Selvarasu K; Singh AK; Dakshinamoorthy A; Sreenivasmurthy SG; Iyaswamy A; Radhakrishnan M; Patnaik S; Huang JD; Williams LL; Senapati S; Durairajan SSK
    Biomedicines; 2023 Dec; 12(1):. PubMed ID: 38275365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific depletion of the motor protein KIF5B leads to deficits in dendritic transport, synaptic plasticity and memory.
    Zhao J; Fok AHK; Fan R; Kwan PY; Chan HL; Lo LH; Chan YS; Yung WH; Huang J; Lai CSW; Lai KO
    Elife; 2020 Jan; 9():. PubMed ID: 31961321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects.
    Falzone TL; Stokin GB; Lillo C; Rodrigues EM; Westerman EL; Williams DS; Goldstein LS
    J Neurosci; 2009 May; 29(18):5758-67. PubMed ID: 19420244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.
    Falzone TL; Gunawardena S; McCleary D; Reis GF; Goldstein LS
    Hum Mol Genet; 2010 Nov; 19(22):4399-408. PubMed ID: 20817925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuronal KIF5b deletion induces striatum-dependent locomotor impairments and defects in membrane presentation of dopamine D2 receptors.
    Cromberg LE; Saez TMM; Otero MG; Tomasella E; Alloatti M; Damianich A; Pozo Devoto V; Ferrario J; Gelman D; Rubinstein M; Falzone TL
    J Neurochem; 2019 May; 149(3):362-380. PubMed ID: 30664247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia.
    Seo J; Kritskiy O; Watson LA; Barker SJ; Dey D; Raja WK; Lin YT; Ko T; Cho S; Penney J; Silva MC; Sheridan SD; Lucente D; Gusella JF; Dickerson BC; Haggarty SJ; Tsai LH
    J Neurosci; 2017 Oct; 37(41):9917-9924. PubMed ID: 28912154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nogo-A Drives Alzheimer's Disease Progression by Inducing Tauopathy Vulnerability.
    Wang Z; Pan JP; Geng J; Lv S; Chen G; Fang N; Zhang Z; Li J; Xu X; Wang R; Zheng Q; Yan L; Chen G; Xiao F
    Aging Dis; 2024 May; ():. PubMed ID: 38916730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology.
    Yang S; Cacquevel M; Saksida LM; Bussey TJ; Schneider BL; Aebischer P; Melani R; Pizzorusso T; Fawcett JW; Spillantini MG
    Exp Neurol; 2015 Mar; 265():48-58. PubMed ID: 25483398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy.
    Mazzaro N; Barini E; Spillantini MG; Goedert M; Medini P; Gasparini L
    J Neurosci; 2016 Feb; 36(7):2086-100. PubMed ID: 26888921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nmnat1 protects neuronal function without altering phospho-tau pathology in a mouse model of tauopathy.
    Musiek ES; Xiong DD; Patel T; Sasaki Y; Wang Y; Bauer AQ; Singh R; Finn SL; Culver JP; Milbrandt J; Holtzman DM
    Ann Clin Transl Neurol; 2016 Jun; 3(6):434-42. PubMed ID: 27547771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
    van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
    Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
    Liu M; Wang L; Gao J; Dong Q; Perry G; Ma X; Wang X
    J Alzheimers Dis; 2019; 69(4):1077-1087. PubMed ID: 31156179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.
    Mellone M; Kestoras D; Andrews MR; Dassie E; Crowther RA; Stokin GB; Tinsley J; Horne G; Goedert M; Tolkovsky AM; Spillantini MG
    J Neurosci; 2013 Nov; 33(46):18175-89. PubMed ID: 24227726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies.
    Tong BC; Huang AS; Wu AJ; Iyaswamy A; Ho OK; Kong AH; Sreenivasmurthy SG; Zhu Z; Su C; Liu J; Song J; Li M; Cheung KH
    J Biomed Sci; 2022 Oct; 29(1):85. PubMed ID: 36273169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.
    Kraemer BC; Zhang B; Leverenz JB; Thomas JH; Trojanowski JQ; Schellenberg GD
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9980-5. PubMed ID: 12872001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease.
    Ittner LM; Ke YD; Götz J
    J Biol Chem; 2009 Jul; 284(31):20909-16. PubMed ID: 19491104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.
    Zhao D; Zhou Y; Huo Y; Meng J; Xiao X; Han L; Zhang X; Luo H; Can D; Sun H; Huang TY; Wang X; Zhang J; Liu FR; Xu H; Zhang YW
    Cell Death Differ; 2021 Jan; 28(1):337-348. PubMed ID: 32908202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic treatment of behavioral and physiological deficits in a tauopathy mouse model.
    Wang W; Cao Q; Tan T; Yang F; Williams JB; Yan Z
    Aging Cell; 2021 Oct; 20(10):e13456. PubMed ID: 34547169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.